Infant Bacterial Therapeutics AB (9IB) Stock Statistics & Valuation Metrics

Infant Bacterial Therapeutics AB has a market cap or net worth of €82.16M. The enterprise value is €545.68.

Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding. The number of shares has decreased by -2.65% in one year.

Infant Bacterial Therapeutics AB’s return on equity (ROE) is -0.62 and return on invested capital (ROIC) is -58.82%.

The current PE Ratio of Infant Bacterial Therapeutics AB is ―. Infant Bacterial Therapeutics AB’s PEG ratio is 0.20.

In the last 12 months, Infant Bacterial Therapeutics AB had revenue of 0.00 and earned -65.17M in profits. Earnings per share was -4.84.

In the last 12 months, operating cash flow was -56.78M and capital expenditures 0.00, giving a free cash flow of -56.78M billion.

Infant Bacterial Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―

Infant Bacterial Therapeutics AB upcoming earnings date is Aug 26, 2026, TBA (Confirmed).

Infant Bacterial Therapeutics AB as a current ratio of 2.72, with Debt / Equity ratio of 0.00%

In the past 12 months, Infant Bacterial Therapeutics AB has paid 0.00 in taxes.

Infant Bacterial Therapeutics AB EV to EBITDA ratio is -7.87, with an EV/FCF ratio of -7.41.

Infant Bacterial Therapeutics AB has €131.93M in cash and marketable securities with €0.00 in debt, giving a net cash position of €131.93M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Infant Bacterial Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―